Allogene Therapeutics (ALLO) EPS (Weighted Average and Diluted) (2019 - 2026)
Allogene Therapeutics recorded quarterly EPS (Weighted Average and Diluted) of -$0.18 in Q1 2026, down 5.88% quarter-over-quarter from -$0.17 in Q4 2025, and up 35.71% year-over-year from -$0.13 in Q1 2025.
Allogene Therapeutics' EPS (Weighted Average and Diluted) history runs 8 years deep, the most recent figure standing at -$0.18 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 35.71% year-over-year to -$0.18; the TTM figure through Mar 2026 stood at -$0.77 (up 37.4% YoY), while the FY2025 annual figure was -$0.87, up 34.09% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.18 for Q1 2026 at Allogene Therapeutics, down from -$0.17 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.17 in Q4 2025 to a low of -$0.69 in Q1 2023.
- A 5-year average of -$0.4 and a median of -$0.37 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) tumbled 6900.0% in 2022 and surged 45.1% in 2024, its largest moves.
- Allogene Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.68 in 2022, then gained by 25.0% to -$0.51 in 2023, then soared by 45.1% to -$0.28 in 2024, then surged by 39.29% to -$0.17 in 2025, then fell by 5.88% to -$0.18 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.18, -$0.17, and -$0.19 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Allogene Therapeutics | 521.43 Mn | 521.43 Mn | - | -0.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.18 |
| Dec 31, 2025 | -0.17 |
| Sep 30, 2025 | -0.19 |
| Jun 30, 2025 | -0.23 |
| Mar 31, 2025 | -0.28 |
| Dec 31, 2024 | -0.28 |
| Sep 30, 2024 | -0.32 |
| Jun 30, 2024 | -0.35 |
| Mar 31, 2024 | -0.38 |
| Dec 31, 2023 | -0.51 |
| Sep 30, 2023 | -0.37 |
| Jun 30, 2023 | -0.54 |
| Mar 31, 2023 | -0.69 |
| Dec 31, 2022 | -0.68 |
| Sep 30, 2022 | -0.59 |
| Jun 30, 2022 | -0.56 |
| Mar 31, 2022 | -0.56 |
| Dec 31, 2021 | 0.01 |
| Sep 30, 2021 | -0.57 |
| Jun 30, 2021 | -0.53 |
| Mar 31, 2021 | -0.25 |
| Dec 31, 2020 | -1.08 |
| Sep 30, 2020 | -0.52 |
| Jun 30, 2020 | -0.53 |
| Dec 31, 2019 | -0.60 |